Coronary and systemic hemodynamic effects of intravenous nisoldipine by Soward, A.L. et al.
Coronary and Systemic Hemodynamic Effects 
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and PATRICK W. SERRUYS, MD 
Systemic and coronary hemodynamic effects of the 
new dihydropyridine calcium antagonist nisoldipine 
were studied over a 30-minute period in 12 patients 
with angina pectoris. Previously instituted p-blocker 
therapy was continued. Nisoldipine was adminis- 
tered in an intravenous bolus of 6 pg/kg over 3 
minutes. Heart rate increased as mean aortic pres- 
sure and systemic vascular resistance decreased in 
all patients. Cardiac output increased significantly, 
from 5.6 f 0.3 to 7.9 f 0.5 liters/min, 10 minutes 
after nisoldipine infusion. These trends were main- 
tained over the 30-minute observation period. Coro- 
nary sinus blood flow increased from 103 41 11 to 
139 f 13 ml/min immediately after nisoldipine, but 
had returned to the control level by 30 minutes, as 
had the reduction in coronary vascular resistance. 
Myocardial oxygen consumption and heart rate- 
systolic blood pressure product did not change sig- 
nificantly. Nisoldipine is a potent peripheral and 
coronary vasodilator free of major myocardial de- 
pressant effects after acute intravenous administra- 
tion. The systemic vasodilatory effects appear to 
outlast the coronary effects over 30 minutes. 
(Am J Cardiol 1966;58:1199-1203) 
N isoldipine is a calcium channel blocking agent of 
the dihydropyridine class, similar in chemical struc- 
ture to nifedipine.‘,’ Nisoldipine has 4 to 10 times the 
potency of nifedipine in inhibiting vascular smooth 
muscle, but is less potent in the inhibition of isolated 
heart muscle.3 Nisoldipine may have a preferential 
effect on the coronary vasculature in vivo,4 a potential- 
ly desirable effect for treatment of myocardial ische- 
mia. The acute effects in humans of intravenous nisol- 
dipine on coronary and peripheral vasculature and 
left ventricular function were recently shown.5-6 The 
increase in heart rate after nisoldipine administration 
and the lack of observed negative inotropic effects 
indicate that in clinical usage, nisoldipine may be 
combined with a /3-adrenergic blocking drug. There- 
fore, in this study the patients continued to receive any 
prescribed P-blocking drug. The aim was to investigate 
the persistence of hemodynamic changes induced by a 
bolus of nisoldipine over a 30-minute study period. 
From the Cardiac Catheterization I,a\)oratory, Thoraxccnter, 
Erasmus LJnivcrsity, Rotterdam, The Netherlands. Manuscript 
received Jul?; 31,1985: revised manuscript rcceivcd July 21.3986, 
accepted July 22, 1906. 
Address for reprints: Patrick W. Scrruys, MD, Thorax Ccn- 
tw, Catheterization Laboratory. P.O. Box 1738, 3000 DR Rotter- 
dam, The Ncthcrlands. 
Methods 
Twelve patients (10 men, 2 women] undergoing car- 
diac catheterization for investigation of suspected cor- 
onary artery disease were studied. Mean age was 54 
years (range 37 to 64) (Table I]. All medications except 
/3-adrenergic blocking drugs were discontinued at 
least 24 hours before the study. Beta-blocker therapy 
was continued in the dose prescribed by the referring 
physician. Cardiac catheterization was performed 
with the patient fasting and without premeditation 
using a right antecubital approach. A Webster coro- 
nary sinus thermodilution catheter was positioned to 
allow recording of coronary sinus blood flow by the 
continuous thermodilution technique7 and sampling of 
blood for oxygen saturations. The catheter position 
was determined by initial contrast injection and subse- 
quent fluoroscopy and was kept stable. A No. 7Fr 
Swan-Ganz thermodilution catheter was positioned 
with the tip at the bifurcation of the main pulmonary 
artery for pressure measurements and determination 
of cardiac output. A No. 8Fr Millar pigtail catheter 
with tip manometer for pressure recording was posi- 
tioned in the ascending aorta. Blood for aortic oxygen 
saturation could be taken through this catheter. 
Nisoldipine, 6 pg/kg, was infused intravenously 
over 3 minutes, with care taken to minimize exposure 
to light. Heart rate, coronary sinus blood flow, aortic, 
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TABLE I Patient Clinical and Anglographic Data 
Fi Age (yr) 8 Sex Beta Blocker Dose 0x7) Time (hr) Prior Infarct 
1 54M 
2 58M 
3 50M 
4 50M 
5 42M 
6 56M 
7 64M 
a 56M 
9 54F 
10 64F 
11 59M 
12 37M 
Metoprolol 
Atenolol 
Atenolol 
Metoprolol 
Metoprolol 
Metoprolol 
Metoprolol 
Metoprolol 
Atenolol 
Propranolol 
2 x 50 6 
1 x 100 4 
1 x 106 2 
2 x 50 2 
2 X 25 2 
2 x 50 3 
2 x 50 6 
2 x 100 6 
3 x 50 6 
4x 10 4 
t 
+ 
- 
- 
+ 
+ 
- 
t 
- 
- 
+ 
- 
EF (%) 
0.71 
0.46 
0.62 
0.74 
0.39 
0.35 
0.71 
0.45 
0.59 
0.73 
0.67 
0.65 
Time (hr) = time between last intake of B blocker and study. 
CAD = coronary artery disease; EF = left ventricular ejection fraction. 
pulmonary and right atria1 pressures, aortic and coro- 
nary sinus oxygen saturations and cardiac output were 
measured in the control state before nisoldipine 
infusion and as close as possible to lo,20 and 30 min- 
utes after completion of the infusion. Heart rate, oxy- 
gen saturations and coronary sinus blood flow were 
measured again immediately upon cessation of nisol- 
dipine infusion and hemoglobin levels were deter- 
mined before and after the study. Standard left ven- 
triculography and coronary angiography were then 
performed. Left ventricular ejection fractions were 
calculated from the right anterior oblique projection. 
Aortic and coronary sinus oxygen contents were given 
by hemoglobin (g/l00 ml) X oxygen saturation X 1.36, 
myocardial oxygen consumption by coronary blood 
flow X aortocoronary sinus oxygen difference and pe- 
ripheral vascular resistance by the ratio of mean aortic 
- right atria1 pressure difference to cardiac output. 
Coronary vascular resistance was given by the ratio of 
mean aortic pressure to mean coronary blood flow. 
Statistical analysis: Values are mean f standard 
error of the mean, using .&way analysis of variance 
(Duncan new multiple-range test) for repeated mea- 
surements. When overall significance was found, mul- 
tiple comparisons were used to delineate which paired 
comparisons were significantly different at the 0.05 
level. 
Results 
Ten patients were taking p-blocking drugs and 11 
had significant coronary artery disease, defined as at 
least 50% luminal diameter narrowing in a major coro- 
nary artery. Mean ejection fraction was 0.59 (range 
0.35 to 0.74). There was no difference in hemoglobin 
values measured before and after the study. Patient 
clinical and angiographic data are summarized in Ta- 
ble 1. No patient had angina pectoris or other untoward 
symptoms during the study. 
Heart rate increased and systemic vascular resis- 
tance decreased with a decrease in mean aortic pres- 
sure in all patients (Fig. 1). Cardiac output had in- 
creased from 5.8 f 0.3 to 7.9 f 0.5 liters/min (36 f 470, 
p <0.05) at 10 minutes to 7.2 f 0.5 liters/min (24 f 370, 
p <0.05) at 20 minutes and was still significantly ele- 
vated at 6.8 f 0.4 liters/min (18 f 3%, p <0.05) at 30 
minutes after nisoldipine. Control stroke volume was 
91 f 5 ml and increased by 17 f 3% (p <0.05) at 10 
minutes, by 7 f 2% (p <0.05) at 20 minutes and by 6 f 
2% (p <O.O5) at 30 minutes. The indexes of these mea- 
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FIGURE 1. Changes in heart rate (H.R.), mean aortic (AO) pressure 
and systemic vascular resistance (S.V.R.) before (C) and at 10, 20 
and 30 minutes after nisoldiplne. The p values are given with re- 
spect to control measurements. 
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surements are displayed in Figure 2. An increase in 
coronary sinus blood flow occurred in all patients, as 
did a fall in coronary vascular resistance. The lowest 
percentage increase in coronary sinus blood flow oc- 
curred in the 2 patients with the lowest ejection frac- 
tions. Mean control flow was 103 f 11 ml/min, in- 
creasing to 139 f 13 ml/min (38 f 970, p <0.05) 
immediately after nisoldipine infusion. At 10 minutes 
the change was 23 f 970 (p <0.05), at 20 minutes 13 f 
4% (p <0.05] and by 30 minutes the mean coronary 
flow had returned to the control value. Coronary vas- 
cular resistance decreased from 1.15 f 0.13 to 0.66 f 
0.08 mm Hg/ml/min (40 f 470, p <0.05) immediately 
after nisoldipine. At 10 minutes it had decreased 25 f 
5% (p <0.05), at 20 minutes 18 f 4% (p 0.01) and at 30 
minutes 9 f 670 (difference not significant] (Fig. 3). 
The increases in myocardial oxygen consumption of 
470, 370 and 270 at 0, 10 and 20 minutes after nisoldi- 
pine infusion were not significant, nor was the 1070 
decrease (p = 0.8) at 30 minutes. Systolic aortic pres- 
sure-heart rate product was unchanged. Correcting 
myocardial oxygen consumption for heart rate pro- 
duced a decrease of 1870 (p <0.05) immediately after, 
207~ (p <0.05) at10 minutes, 11% (p <0.05) at 20 min- 
utes and 12% (difference not significant] at 30 minutes 
after nisoldipine. Thus, at least to 20 minutes after 
nisoldipine, perfusion remains in excess of demand. 
Mean pulmonary arterial pressure was slightly in- 
creased at 10 minutes after nisoldipine, from 18 f 2 to 
20 f 2 mm Hg (17 f 670, p <0.05) but had returned to 
the control value at 20 minutes. Similar changes oc- 
curred in mean right atria1 pressures. 
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FIGURE 2. Mean cardiac index (Cl.) and stroke volume index 
(S.V.I.) before (C) and 10, 20 and 30 mlnutes afler nlsoldlplne. The 
p values are given wlth respect to control measurements. 
Discussion 
This study confirms the persistence of some hemo- 
dynamic effects over 30 minutes after an intravenous 
bolus of nisoldipine. Heart rate, stroke volume and 
cardiac output remained elevated at 30 minutes, aortic 
pressures and systemic vascular resistance were de- 
creased. In this regard nisoldipine mimics the effects 
of nifedipine with afterload reduction inducing reflex 
sympathetic activation8 
Since approximately 857~ of coronary sinus blood 
flow arises from the left ventricle,9 measurements re- 
flect left ventricular coronary flow. Research data sup- 
port a very close link between myocardial oxygen de- 
mand and coronary blood flow, with the changing 
oxygen requirements producing alterations in coro- 
nary vascular resistance and flow on a beat-to-beat 
basis.‘” Thus, the increase in flow observed after nisol- 
dipine in the face of an unchanged myocardial oxygen 
consumption reflects a perfusion of the left ventricle in 
excess of demand, one means by which calcium antag- 
onists may be beneficial in the treatment of ischemia. 
To be beneficial, such increased supply should be dis- 
tributed to ischemic or potentially ischemic myocardi- 
urn as well as to normal area. In dogs with acutely 
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FIGURE 3. Mean coronary sinus blood flow (C.S.B.F.) and coronary 
vascular resistance (C.V.R.) before (C), immediately after, and 10, 
20 and 30 minutes afler nisoldipine. The p values are given with 
respect to control measurements. 
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occluded left anterior descending arteries, nisoldipine 
increases coronary collateral flow to the ischemic 
zone, with equal distribution to the subendocardium 
and subepicardium. l1 A study of 10 patients with coro- 
nary artery disease, using a C-l4 lactate infusion and 
coronary sinus lactate estimations, suggested that ni- 
soldipine reduced lactate production by chronically 
underperfused myocardium.lz While increased oxy- 
gen supply was considered to play a part, dipyrida- 
mole, a powerful coronary dilator, has few antianginal 
properties and does not improve myocardial lactate 
metabolism, indicating that other actions of nisoldi- 
pine may be operative in myocardial ischemia. Reduc- 
tion of left ventricular preload is considered an impor- 
tant component of the antianginal action of nitrates. 
While nifedipine has little such tendency,13 nisoldi- 
pine was shown to reduce markedly left ventricular 
end-diastolic pressure in fluid-loaded pigs without de- 
pression of myocardial contractility.14 It was suggested 
that antianginal effects of nisoldipine may include cor- 
rection of impaired ventricular relaxation with reduc- 
tion in diastolic wall stress. 
At lo,20 and 30 minutes, a greater degree of reduc- 
tion in vascular resistance was present in the systemic 
than in the coronary system [Fig. 4). In an earlier study 
coronary vascular resistance was reduced by 50% im- 
mediately after nisoldipine, while systemic vascular 
resistance was reduced by 3O%, suggesting relative 
selectivity for the coronary vasculature.5 Such selec- 
tivity could result from an increased number of nisol- 
dipine receptor sites or receptors of greater sensitivity 
in the coronary vascular wall, The duration and de- 
gree of systemic effects of nisoldipine in the current 
study may be due to the fact that coronary vascular 
autoregulation became operative within the 30-minute 
observation period. Although the mediators of this 
control that couples vascular resistance to myocardial 
metabolism are unknown, adenosine and other nucle- 
otides, prostaglandins, carbon dioxide and hydrogen 
ions have been proposed as possibilities. Although 
autoregulation is not unique to the coronary circula- 
tion and also occurs in peripheral vascular beds, coro- 
nary autoregulatory mechanisms may be more potent 
in effecting a return of the nisoldipine-induced 
changes toward control. Other explanations for the 
observed changes include peripheral vascular selec- 
tivity for nisoldipine rather than coronary selectivity3 
or disparate effects on the coronary vasculature of va- 
soconstrictors such as noradrenaline released by re- 
flex sympathetic mechanisms. 
Beta-blocking drugs used alone produce reductions 
in myocardial oxygen consumption, increase coronary 
vascular resistance15,16 and reduce blood flow,17 
changes that may increase sensitivity to the vasodilator 
effects of nisoldipine. The lack of control data before 
P-blocker therapy makes it difficult to speculate on the 
additive effects in the 10 patients taking these medica- 
tions. Certainly the increase in heart rate was similar to 
that observed in the previous study, in which P- 
blocker therapy was discontinued.5J Some patients 
were, however, using P-blocker dosages lower than 
those generally recommended, and the rest heart rate 
in a few suggests uboptimal /3 blockade. Studies with 
nifedipine and ,&blocking drugs show attenuation 
of the reflex positive inotropic and chronotropic 
changes.17J8 As the increase in heart rate after nisoldi- 
pine tended to offset any reduction in cardiac work, 
the combination with p blockade may be beneficial. 
The increase in right heart pressures probably 
reflects the increase in venous return. The absence 
of venodilatory effects has been shown for nifedi- 
pine,lg but has not been investigated in humans for 
nisoldipine. 
In a recent study on open-chested anesthetized 
dogs, nisoldipine reduced myocardial infarct size after 
coronary occlusion by 31.4% .2o This was considered to 
be in part a result of afterload reduction with reduced 
left ventricular wall stress, as it was pointed out that 
other agents producing afterload reduction such as 
nitroprusside have been ineffective in preventing 
ischemic myocardial damage.z1z22 Other animal ex- 
periments with nisoldipine show it to be useful in pre- 
venting ventricular arrhythmias resulting from acute 
myocardial ischemia in ratsz3 and effective in prevent- 
ing ATP breakdown in the ischemic rat heart.24 In the 
latter study, ischemia was induced by lowering aortic 
perfusion and nisoldipine was given through the aorta. 
Nisoldipine was found to induce coronary vasodilata- 
tion at very low doses and a significant negative inotro- 
pit effect only became apparent at concentrations 30 
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FIGURE 4. Individual percent changes in systemic vascular resis- 
tance (S.V.R.) and coronary vascular resistance (C.V.R.) at 10 
minutes (Wang/es, n = 1 l), 20 (squares, n = 11) and 30 minutes 
(dots, n = 10) after nisoldipine. Mean changes (A standard error) 
are shbwn by the hollow symbols. Broken line indicates the line of 
identity. 
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times higher. Purine efflux from the ischemic hearts 
was suppressed in a dose-dependent fashion, suggest- 
ing preservation of myocardial ATP. A direct effect on 
myocardial enzyme levels was postulated. With the 
afterload-reducing properties of nisoldipine, the lack 
of significant negative inotropic effects from doses 
producing the vascular changes and the possibility of 
reducing infarct size, the drug may have clinical use- 
fulness for treatment of acute myocardial infarction 
complicated by increased systemic blood pressure. 
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